Rapport Therapeutics director Healy buys $20.3M in shares
Covered in this story
Analyst targets on Rapport Therapeutics Inc
- Raymond James: $29.4 → $86 by Oct 2027 · Strong Buy via Investing.com
- Truist Securities: $29.4 → $56 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RAPP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Rapport Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.